Avaleht › Autoimmuunhaigused › California
Autoimmuunhaigused kliinilised uuringud osariigis California
27 uuringut haiguse Autoimmuunhaigused jaoks otsivad osalejaid osariigis California.
Linnad osariigis California
- Los Angeles12 uuringut
- Orange7 uuringut
- San Francisco7 uuringut
- Mountain View6 uuringut
- San Diego5 uuringut
- Sacramento5 uuringut
- Irvine3 uuringut
Ametlik uuringutekst (inglise keeles)
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- City of Hope Comprehensive Cancer Center, Duarte
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 1. okt 2026 · NCT06817889A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Chula Vista
VärbamineFaas 2
Vanused 18–60 · Kõik sood · Uuendatud 25. sept 2026 · NCT07541287Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 23. sept 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 18. sept 2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of California Irvine - Accepting Adult Patients, Orange
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients, San Francisco
VärbamineFaas 2/3
Vanused 6–75 · Kõik sood · Uuendatud 17. sept 2026 · NCT06154252A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
- University of Southern California, Los Angeles
VärbamineFaas 3
Vanused 18–70 · Kõik sood · Uuendatud 11. sept 2026 · NCT07059000A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
VärbamineFaas 1
Vanused 18–74 · Kõik sood · Uuendatud 10. sept 2026 · NCT07085104A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 9. sept 2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Orange
- ja veel 2
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 8. sept 2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of California Irvine, Orange
- UC Davis Health, Sacramento
VärbamineFaas 1/2
Vanused 18–65 · Kõik sood · Uuendatud 26. aug 2026 · NCT06121297RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- University of California Irvine, Orange
- UC Davis, Department of Neurology, Sacramento
- University of California, San Francisco, San Francisco
VärbamineFaas 1/2
Vanused 18–70 · Kõik sood · Uuendatud 13. aug 2026 · NCT06359041A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- UC Irvine, Irvine
- Orso Health, La Jolla
- University of California, Los Angeles-UCLA, Los Angeles
VärbamineFaas 3
Vanused 12 ja vanemad · Kõik sood · Uuendatud 6. aug 2026 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-103, South Gate
VärbamineFaas 1
Vanused 18–65 · Kõik sood · Uuendatud 31. juuli 2026 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1010, Carlsbad
- Site Number - 1028, Irvine
- Site Number - 1023, Los Angeles
- ja veel 2
VärbamineFaas 3
Vanused 18–80 · Kõik sood · Uuendatud 30. juuli 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Ronald Reagan UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford University Medical Center, Palo Alto
VärbamineFaas 2/3
Vanused 18–75 · Kõik sood · Uuendatud 29. juuli 2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- City of Hope, Duarte
- Children's Hospital of Los Angeles, Glendale
- Scripps Green Hospital, La Jolla
- ja veel 8
VärbamineVaatlusuuring
Kõik vanused · Kõik sood · Uuendatud 6. juuli 2026 · NCT01351545Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
- UCSF Medical Center, San Francisco
- Stanford Medical Center, Stanford
VärbamineFaas 1
Vanused 18–70 · Kõik sood · Uuendatud 30. juuni 2026 · NCT06201416Atacicept in Multiple Glomerular Diseases
- Vera Therapeutics, Brisbane
VärbamineFaas 2
Vanused 2 ja vanemad · Kõik sood · Uuendatud 26. juuni 2026 · NCT06983028A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Stanford University, Dept. of Dermatology, Redwood City
- UC Davis, Dept. of Dermatology, Sacramento
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. mai 2026 · NCT04422912A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- ja veel 2
VärbamineFaas 1
Vanused 12–70 · Kõik sood · Uuendatud 22. mai 2026 · NCT06308978A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
- Stanford Multiple Sclerosis Center, Palo Alto
VärbamineFaas 1
Vanused 18–65 · Kõik sood · Uuendatud 27. veebr 2026 · NCT06138132A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UCLA Medical Center, Los Angeles
- University of California, Irvine, Orange
- Stanford Hospital, Palo Alto
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. veebr 2026 · NCT06626919Central Vein Sign in Multiple Sclerosis Extension Study
- Cedars-Sinai Medical Center, Los Angeles
Värbamine
Vanused 18–65 · Kõik sood · Uuendatud 20. veebr 2026 · NCT07424027CD4^LVFOXP3 in Participants With IPEX
- Lucile Packard Children's Hospital, Palo Alto
VärbamineFaas 1
4 Months – 35 Years · Mehed · Uuendatud 22. mai 2025 · NCT05241444Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
- University of California, San Diego, La Jolla
VärbamineVaatlusuuring
Kõik vanused · Naised · Uuendatud 28. jaan 2025 · NCT02103361Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
- MiraKind, Los Angeles
VärbamineVaatlusuuringTerved vabatahtlikud oodatud
Vanused 18 ja vanemad · Kõik sood · Uuendatud 23. jaan 2025 · NCT02253251Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
VärbamineFaas 1/2Terved vabatahtlikud oodatud
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. apr 2022 · NCT04684602Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.